Myelodysplastic syndrome (MDS) panel

Myelodysplastic syndrome (MDS) is a group of bone marrow disorders characterized by the underproduction of one or more types of blood cells due to a dysfuntion of the marrow. The myelodysplastic syndromes (MDS) may be secondary to treatment with chemotherapy or radiation therapy for another disease.

MDS is characterized by low red blood cells (anemia), low white blood cell count (leukopenia) with a tendency to infection, and low platelet count (thrombocytopenia) with bleeding problems. MDS may progress and transform into acute myelogenous leukemia (AML).

Common chromosome changes would include:

EGR1/D5S630 –5/5q deletion
7cen/D7S486 –7/7q deletion
8cen/c-myc  trisomy 8
D13S319/LAMP1 –13/13q deletion
D20S 108/20qter –20/20 q deletion
RNP1/EVI1 inv(3)(q21;q26)t(3;3

Methodology: Fluorescent in Situ Hybridization (FISH) Analysis

Purpose: Confirmation of Clinical Diagnosis/Monitor During Treatment

ICD-9 Diagnosis: 238.7

Test Requisition: Cancer Cytogenetics Requisition

CPT Codes: 88271, 88275, 88291 Cost: $341.00 one probe

Turn-around-time: 2-5 days